Torrent Pharmaceuticals is a pharmaceutical company built on a simple, repeatable playbook: buy established brands and businesses, plug them into a low-cost Indian manufacturing engine, and push them through a growing army of medical representatives who drive prescriptions from doctors. It began in 1959 when founder U. N. Mehta, a former medical representative, made niche marketing the company’s core skill, and it has since scaled into a global operation spanning more than 50 countries through a string of carefully chosen acquisitions. The recurring pattern is visible across every phase of its history - acquire a target with strong brands or a market position, integrate it, and then expand its reach using Torrent’s own field force and manufacturing backbone.
Business segments
Three engines at different stages - a dominant Indian branded-generics platform recently enlarged by a landmark acquisition, a German generics business built on a two-decade-old purchase, and a Brazilian branded-generics operation that leads among Indian peers - all fed by a shared manufacturing and R&D backbone.
1. India branded generics: the prescription-driven core
Torrent sells affordable, branded versions of off-patent drugs into India’s chronic-disease market, where a field force of over 9,000 medical representatives turns doctor relationships into recurring prescriptions filled through a network of more than 6,100 stockists.
- Chronic therapies mean repeat business - chronic and sub-chronic conditions account for 75% of Torrent’s India revenue, well above the 56% industry average, so a prescription once written tends to refill for years.
- The field force is the distribution channel - medical representatives visit over 200,000 healthcare professionals, and the sales structure is organised by therapy area with low staff turnover, which keeps the team focused and effective in clinics.
- Acquisitions deliver ready-made brand franchises - the purchase of JB Pharma, now being merged, added six iconic brands ranked among India’s top 300 and made the combined entity the country’s fourth-largest pharma company by prescriptions.
- First-to-market launches build early leads - Torrent launched India’s first generic Semaglutide in both injectable and oral forms and held a 38% share among generic players by April 2026, while a first-to-market generic in psychiatry and a Phase 3 trial for a NASH drug aim to repeat that pattern.
- A consumer-health leg reaches patients directly - the over-the-counter business, including the Curatio cosmetic-dermatology portfolio, grew 27% in FY26 and now gets more than a fifth of its sales from ecommerce and quick-commerce platforms.
2. Germany generics: the tender-system specialist
Torrent is the fifth-largest generics player in Germany, a market where insurers award supply contracts through competitive tenders, and the company wins by pairing a broad portfolio with cost-efficient manufacturing.
- Tenders decide who sells - the majority of the German generics market operates through tenders issued by sickness funds, often in single-winner or three-winner models, so revenue rises and falls with tender win rates.
- The portfolio covers more than half the market - Torrent’s product range addresses 56% of the overall German generics market, giving it a wide surface area to compete for tenders.
- Bought, not built from scratch - the German business was established through the 2005 acquisition of Heumann Pharma from Pfizer, and it still leans on licensing arrangements with low-cost manufacturers to keep its cost base competitive.
- Biosimilars are the new frontier - Torrent launched its first biosimilar in Germany and will begin participating in tenders for it, entering a market where automatic substitution rules pull biosimilars into the tender system.
3. Brazil branded generics: the Indian leader in Latin America’s largest market
After 23 years on the ground, Torrent is the top-ranked Indian pharmaceutical company in Brazil, selling branded generics and pure generics through a field force that calls on more than 40,000 physicians every month.
- A dual portfolio for two buyer types - the business sells 33 branded generics to prescription-driven retail customers and 27 pure generics to a pharmacy network that has expanded from roughly 18,000 to over 55,000 outlets per month.
- CNS is the anchor - in a Brazilian central-nervous-system market worth more than $3 billion, Torrent grew 12% and holds a 14% share, with individual brands commanding volume shares as high as 75% in epilepsy and 45% in schizophrenia.
- Cardio-diabetes brands own their niches - Nebivolol is the most-prescribed brand in its class with a 50% market share, and Gliclazida leads sulfonylureas with over 80% of the market.
- Oncology opens a new lane - Torrent received approval for and launched its first oncology product in Brazil, adding a therapy area to a business that already has 58 products under review with the Brazilian regulator.
Manufacturing and R&D backbone
Eight manufacturing sites and a 900-scientist R&D centre supply all three business segments from India, turning out 25 billion tablets and capsules a year with approvals from every major global regulator.
- Scale that leaves headroom - total formulation capacity stands at 25 billion tablets and capsules annually, yet utilisation is only 60%, so the company can absorb new launches and volume growth without building new plants immediately.
- Regulatory clearance is the licence to export - all four facilities supplying the US market are USFDA-compliant, and the Dahej plant moved from an Official Action Indicated classification to voluntary-action-indicated status after a 2023 re-inspection, clearing the path for fresh product approvals.
- Backward integration into active ingredients - two dedicated API plants at Indrad and Vizag together produce 60 metric tonnes per year, reducing dependence on outside suppliers for the raw materials that go into Torrent’s own formulations.
- R&D feeds the pipeline - the Bhat R&D centre spent ₹650 crores in FY26 and filed 19 dossiers across regulated markets, with work spanning complex generics, injectables, oncology, and an expanded push into biologics.
Group structure and partners
Torrent Pharmaceuticals sits at the centre of a web of subsidiaries spanning 15 countries, and its growth has been shaped by a three-decade pattern of buying brands and businesses, then folding them into the parent.
- A multi-continent subsidiary map - the company operates through local entities in the US, Germany, Brazil, Mexico, the UK, South Africa, Russia, Thailand, the Philippines, Malaysia, Australia, Colombia, and Chile, among others.
- Acquisitions are the growth engine - landmark deals include the acquisition of Pfizer's marketing arm (2005) for Germany, Unichem’s India and Nepal business plus a Sikkim plant (2017), Curatio’s cosmetic-dermatology portfolio (2022), and the controlling stake in JB Pharma (2026), now being merged.
- Licensing fills the gaps - Torrent commercialises Vonoprazan for GERD under a licence from Takeda, co-markets a NASH drug with Zydus Lifesciences, and has a three-decade-old partnership supplying human insulin to Novo Nordisk for the Indian market.